Continued Semaglutide 2.4 mg Once Weekly Improved Health Related Quality of Life in the STEP 4 Trial

被引：0
|
作者：
Sharma, Arya
Meincke, Henrik
Jensen, Camilla
Kushner, Robert
Pedersen, Sue
Rubino, Domenica
Tran, Marie
Wharton, Sean
Bjorner, Jakob
机构：
来源：
OBESITY | 2021年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
014
引用
收藏
页码：9 / 10
页数：2
相关论文
共 50 条
  • [1] Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial
    Perreault, Leigh
    Davies, Melanie J.
    Frias, Juan P.
    Laursen, Peter N.
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John
    Wallenstein, Signe O. R.
    Le Roux, Carel
    DIABETES, 2021, 70
  • [2] Once-weekly semaglutide 2.4 mg improved glucose metabolism and prediabetes in adults with overweight or obesity in the STEP 1 trial
    Perreault, L.
    Davies, M.
    Frias, J. P.
    Laursen, P. N.
    Lingvay, I.
    Machineni, S.
    Varbo, A.
    Wilding, J. P. H.
    Wallenstein, S. O. R.
    Le Roux, C. W.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 234 - 234
  • [3] The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials
    Bjorner, Jakob Bue
    Larsen, Sara
    Lubker, Christopher
    Holst-Hansen, Thomas
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2142 - 2150
  • [4] Effect of once-weekly subcutaneous semaglutide 2.4 mg on weight- and health-related quality of life in an East Asian population: Patient-reported outcomes from the STEP 6 trial
    Kolotkin, Ronette L.
    Jeppesen, Ole Kleist
    Baker-Knight, James
    Lee, Sang Yeoup
    Tokita, Asako
    Kadowaki, Takashi
    CLINICAL OBESITY, 2023, 13 (04)
  • [5] Semaglutide 2.4 mg Improves Health -Related Quality of Life in Adults with Overweight/Obesity and Type 2 Diabetes in the STEP 2 Trial
    Rubino, Domenica
    Faerch, Louise
    Meincke, Henrik H.
    Kushner, Robert F.
    Pedersen, Sue
    Ryan, Donna H.
    Wharton, Sean
    Zeuthen, Niels
    Kolotkin, Ronette
    DIABETES, 2021, 70
  • [6] Associations between weight loss and glycaemic control with once-weekly semaglutide 1.0 mg and 2.4 mg in the STEP 2 trial
    Davies, M.
    Faerch, L.
    Goldman, B.
    Pakseresht, A.
    Pedersen, S.
    Rosenstock, J.
    Lingvay, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S254 - S255
  • [7] Once-weekly semaglutide 2.4mg improved metabolic syndrome in adults with overweight or obesity: post hoc analysis of the STEP 1 trial
    Khan, Omar
    le Roux, Carel
    Davies, Melanie
    Frias, Juan
    Laursen, Peter Norkjaer
    Lingvay, Ildiko
    Machineni, Sriram
    Varbo, Anette
    Wilding, John
    Wallenstein, Signe
    Perreault, Leigh
    OBESITY SURGERY, 2022, 32 (SUPPL 1) : 32 - 32
  • [8] The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials
    Alabduljabbar, Khaled
    Al-Najim, Werd
    le Roux, Carel W.
    NUTRIENTS, 2022, 14 (11)
  • [9] Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction
    Wilding, J. P. H.
    Rodbard, H. W.
    Uusinarkaus, K. T.
    Van Gaal, L.
    Hansen, T.
    Sandberg, A. M. L.
    Tadayon, S.
    Davies, M. J.
    DIABETOLOGIA, 2019, 62 : S363 - S364
  • [10] Semaglutide 2.4 mg improves health-related quality of life in adults with overweight or obesity and type 2 diabetes in the STEP 2 trial
    Rubino, D. M.
    Faerch, L.
    Meincke, H. H.
    Kushner, R. F.
    Pedersen, S. D.
    Ryan, D. H.
    Wharton, S.
    Zeuthen, N.
    Kolotkin, R. L.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 248 - 249
12345